Rocket Pharmaceuticals (RCKT) Stock Rises On Gene Therapy Advancement
After obtaining a significant regulatory designation, investor confidence in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) surged. Thursday saw a 16.78% increase in RCKT shares, which ended the trading day at $3.34. The momentum comes after the U.S. Food and Drug Administration (FDA) announced that Rocket’s gene therapy candidate, RP-A601, has been designated as a Regenerative Medicine […]
Rocket Pharmaceuticals (RCKT) Touches 5-Year High on Positive Gene Expression; Also, Prices Upsized Common Stock Offering
Rocket Pharmaceuticals reports promising Phase 1 data from its gene therapy in heart disease. RCKT shares skyrocketed, reaching a five-year high of $63.94. The pharmaceutical firm upsizes its public offering of 4.6 million of its common stock, valued at $260 million. Shares of Rocket Pharmaceuticals, Inc. (RCKT) rallied to their 5-years high after the company […]